Skip to main content
. 2021 Mar 1;14(3):322–337.

Table 1.

Baseline clinicopathologic characteristics of breast cancer participants

Feature No. of patients (%) n=522
Age group
    <40 69 (13.2)
    40-49 144 (27.6)
    50-59 188 (35.9)
    60-69 86 (16.5)
    ≥70 35 (6.7)
Age
    Young (≤40 Y-O) 81 (69.8)
    Older (≥70 Y-O) 35 (30.2)
Tumor location
    Right 234 (44.8)
    Left 285 (54.6)
    Bilateral 3 (0.6)
Tumor size (cm)
    ≤2 261 (50.0)
    >2-5 242 (46.4)
    >5 19 (3.6)
pTNM stage
    I 134 (25.7)
    II 306 (58.6)
    III 82 (15.7)
Risk category
    Low 24 (4.6)
    Intermediate 359 (68.8)
    High 139 (26.6)
Outcome
    Die 24 (12.3)
    Survival 171 (87.7)
Recurrence
    No Relapse 192 (98.5)
    Relapse 3 (1.5)
Histopathologic type
    Invasive ductal, NOS 374 (71.6)
    Mucinous 16 (3.1)
    Lobular 89 (17.0)
    Other 43 (8.2)
Histologic grade
    I 56 (10.7)
    II 190 (36.4)
    III 276 (52.9)
Lymph node status
    Negative 330 (63.2)
    1-3 positive node (s) 121 (23.2)
    >3 positive nodes 71 (13.6)
Nottingham PI
    Good 122 (23.4)
    Moderate 281 (53.8)
    Poor 119 (22.8)
LVI
    Negative 337 (64.6)
    Positive 185 (35.4)
Tumor necrosis
    Negative 429 (82.2)
    Positive 93 (17.8)
Ki67 index
    Low (≤20%) 271 (51.9)
    High (>20%) 251 (48.1)